In ex vivo slices, we demonstrated antiseizure effects of everolimus and these effects were more pronounced in TSC and FCD cases compared to non-mTOR-mediated pathologies (Cepeda et al., 2018). This evidence concerns the gene MTOR and tuberous sclerosis.